G. Jawahar Swaminathan

G. Jawahar Swaminathan

Auto-generated profile, based on publicly available information

G. Jawahar Swaminathan

Protein Data Bank in Europe, EMBL-EBI, Wellcome Trust Genome Campus, Hinxton, Cambridge CB10 1SD, UK

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in The Lancet
Verified
Journal Article
Open access
CWCaroline F Wright
Caroline F Wright
TFTomas W Fitzgerald
Tomas W Fitzgerald
WJWendy D Jones
Wendy D Jones
SCStephen Clayton
Stephen Clayton
JMJeremy F McRae
Jeremy F McRae
HFHelen V Firth
Helen V Firth
Human genome sequencing has transformed our understanding of genomic variation and its relevance to health and disease, and is now starting to enter clinical practice for the diagnosis of rare diseases. The question of whether and how some categories of genomic findings should be shared with individual research participants is currently a topic of international debate, and development of robust analytical workflows to identify and communicate clinically relevant variants is paramount. The Deciphering Developmental Disorders (DDD) study has developed a UK-wide patient recruitment network involving over 180 clinicians across all 24 regional genetics services, and has performed genome-wide microarray and whole exome sequencing on children with undiagnosed developmental disorders and their parents. After data analysis, pertinent genomic variants were returned to individual research participants via their local clinical genetics team. Around 80,000 genomic variants were identified from exome sequencing and microarray analysis in each individual, of which on average 400 were rare and predicted to be protein altering. By focusing only on de novo and segregating variants in known developmental disorder genes, we achieved a diagnostic yield of 27% among 1133 previously investigated yet undiagnosed children with developmental disorders, whilst minimising incidental findings. In families with developmentally normal parents, whole exome sequencing of the child and both parents resulted in a 10-fold reduction in the number of potential causal variants that needed clinical evaluation compared to sequencing only the child. Most diagnostic variants identified in known genes were novel and not present in current databases of known disease variation. Implementation of a robust translational genomics workflow is achievable within a large-scale rare disease research study to allow feedback of potentially diagnostic findings to clinicians and research participants. Systematic recording of relevant clinical data, curation of a gene-phenotype knowledge base, and development of clinical decision support software are needed in addition to automated exclusion of almost all variants, which is crucial for scalable prioritisation and review of possible diagnostic variants. However, the resource requirements of development and maintenance of a clinical reporting system within a research setting are substantial. Health Innovation Challenge Fund, a parallel funding partnership between the Wellcome Trust and the UK Department of Health.

13 August 2015 in Human Mutation
Verified
Journal Article
Open access
PDF file
APAnthony A. Philippakis
Anthony A. Philippakis
DADanielle R. Azzariti
Danielle R. Azzariti
SBSergi Beltran
Sergi Beltran
ABAnthony J. Brookes
Anthony J. Brookes
CBCatherine A. Brownstein
Catherine A. Brownstein
HHeidi Rehm
Heidi Rehm
There are few better examples of the need for data sharing than in the rare disease community, where patients, physicians, and researchers must search for “the needle in a haystack” to uncover rare, novel causes of disease within the genome. Impeding the pace of discovery has been the existence of many small siloed datasets within individual research or clinical laboratory databases and/or disease‐specific organizations, hoping for serendipitous occasions when two distant investigators happen to learn they have a rare phenotype in common and can “match” these cases to build evidence for causality. However, serendipity has never proven to be a reliable or scalable approach in science. As such, the Matchmaker Exchange (MME) was launched to provide a robust and systematic approach to rare disease gene discovery through the creation of a federated network connecting databases of genotypes and rare phenotypes using a common application programming interface (API). The core building blocks of the MME have been defined and assembled. Three MME services have now been connected through the API and are available for community use. Additional databases that support internal matching are anticipated to join the MME network as it continues to grow.

21 October 2013 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
EBEugene Bragin
Eugene Bragin
ECEleni A. Chatzimichali
Eleni A. Chatzimichali
CWCaroline F. Wright
Caroline F. Wright
MHMatthew E. Hurles
Matthew E. Hurles
HFHelen V. Firth
Helen V. Firth
GSG. Jawahar Swaminathan
G. Jawahar Swaminathan
The DECIPHER database (https://decipher.sanger.ac.uk/) is an accessible online repository of genetic variation with associated phenotypes that facilitates the identification and interpretation of pathogenic genetic variation in patients with rare disorders. Contributing to DECIPHER is an international consortium of >200 academic clinical centres of genetic medicine and ≥1600 clinical geneticists and diagnostic laboratory scientists. Information integrated from a variety of bioinformatics resources, coupled with visualization tools, provides a comprehensive set of tools to identify other patients with similar genotype–phenotype characteristics and highlights potentially pathogenic genes. In a significant development, we have extended DECIPHER from a database of just copy-number variants to allow upload, annotation and analysis of sequence variants such as single nucleotide variants (SNVs) and InDels. Other notable developments in DECIPHER include a purpose-built, customizable and interactive genome browser to aid combined visualization and interpretation of sequence and copy-number variation against informative datasets of pathogenic and population variation. We have also introduced several new features to our deposition and analysis interface. This article provides an update to the DECIPHER database, an earlier instance of which has been described elsewhere [Swaminathan et al. (2012) DECIPHER: web-based, community resource for clinical interpretation of rare variants in developmental disorders. Hum. Mol. Genet., 21, R37–R44].

5 October 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
TSthe DDD study
the DDD study
NANadia Akawi
Nadia Akawi
JMJeremy McRae
Jeremy McRae
MAMorad Ansari
Morad Ansari
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
MHMatthew E Hurles
Matthew E Hurles

10 December 2008 in Molecular Biotechnology
Verified
Journal Article
Closed access
PDF file
SDShuchismita Dutta
Shuchismita Dutta
KBKyle Burkhardt
Kyle Burkhardt
JYJasmine Young
Jasmine Young
GSGanesh J. Swaminathan
Ganesh J. Swaminathan
TMTakanori Matsuura
Takanori Matsuura
HBHelen M Berman
Helen M Berman

11 December 2007 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
KHKim Henrick
Kim Henrick
ZFZukang Feng
Zukang Feng
WBWolfgang F. Bluhm
Wolfgang F. Bluhm
DDDimitris Dimitropoulos
Dimitris Dimitropoulos
JDJurgen F. Doreleijers
Jurgen F. Doreleijers
HBHelen M Berman
Helen M Berman
The Worldwide Protein Data Bank (wwPDB; wwpdb.org) is the international collaboration that manages the deposition, processing and distribution of the PDB archive. The online PDB archive at ftp://ftp.wwpdb.org is the repository for the coordinates and related information for more than 47 000 structures, including proteins, nucleic acids and large macromolecular complexes that have been determined using X-ray crystallography, NMR and electron microscopy techniques. The members of the wwPDB–RCSB PDB (USA), MSD-EBI (Europe), PDBj (Japan) and BMRB (USA)–have remediated this archive to address inconsistencies that have been introduced over the years. The scope and methods used in this project are presented.